| 1 | STELMACH P, TRUMPP A. Leukemic stem cells and therapy resistance in acute myeloid leukemia[J]. Haematologica, 2023, 108(2): 353-366. | 
																													
																							| 2 | SU H, NA N, ZHANG X, et al.. The biological function and significance of CD74 in immune diseases[J]. Inflamm. Res., 2017, 66(3): 209-216. | 
																													
																							| 3 | SANCHEZ-NIÑO M D, SANZ A B, RUIZ-ANDRES O, et al.. MIF, CD74 and other partners in kidney disease: tales of a promiscuous couple[J]. Cytokine Growth Factor Rev., 2013, 24(1): 23-40. | 
																													
																							| 4 | KASHIMA Y, SHIBAHARA D, SUZUKI A, et al.. Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer[J]. Cancer Res., 2021, 81(18): 4835-4848. | 
																													
																							| 5 | LASKIN J, LIU S V, TOLBA K, et al.. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents[J]. Ann. Oncol., 2020, 31(12): 1693-1703. | 
																													
																							| 6 | D·M·戈登伯格,H·汉森,S·-O·梁,等. 内在化抗-CD74抗体和使用方法: CN 03809863.6[P].2011-04-13. | 
																													
																							| 7 | 范蓓,王园园,赵云霞,等.免疫系统人源化小鼠模型构建技术探讨[J].生物技术进展,2022,12(6):922-928. | 
																													
																							|  | FAN B, WANG Y Y, ZHAO Y X, et al.. Discussion on the construction technology of mouse model with mumanized immune[J]. Curr. Biotechnol., 2022, 12(6): 922-928. | 
																													
																							| 8 | LIU H. Emerging agents and regimens for AML[J/OL]. J. Hematol. Oncol., 2021, 14(1): 49[2024-04-10]. . | 
																													
																							| 9 | 张鹏晓,胡念.黑色素瘤免疫治疗作用机制研究进展[J].生物技术进展,2023,13(6):900-906. | 
																													
																							|  | ZHANG P X, HU N. The research progress on action mechanism of melanoma immunotherapy[J]. Curr. Biotechnol., 2023, 13(6): 900-906. | 
																													
																							| 10 | 高朗,于思雪,袁春森,等.黏蛋白在肿瘤免疫治疗中的研究进展[J].生物技术进展,2023,13(3):390-398. | 
																													
																							|  | GAO L, YU S X, YUAN C S, et al.. Research progress of mucin in tumor immunotherapy[J]. Curr. Biotechnol., 2023, 13(3): 390-398. | 
																													
																							| 11 | MILES R R, CAIRO M S, SATWANI P, et al.. Immunophenotypic identification of possible therapeutic targets in paediatric non-hodgkin lymphomas: a children's oncology group report[J]. Br. J. Haematol., 2007, 138(4): 506-512. | 
																													
																							| 12 | BURTON J D, ELY S, REDDY P K, et al.. CD74 is expressed by multiple myeloma and is a promising target for therapy[J]. Clin. Cancer Res., 2004, 10(19): 6606-6611. | 
																													
																							| 13 | MCCLELLAND M, ZHAO L, CARSKADON S, et al.. Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer[J]. Am. J. Pathol., 2009, 174(2): 638-646. | 
																													
																							| 14 | CONROY H, MAWHINNEY L, DONNELLY S C. Inflammation and cancer: macrophage migration inhibitory factor (MIF): the potential missing link[J]. QJM-Int.J.Med., 2010, 103(11): 831-836. | 
																													
																							| 15 | STEIN R, MATTES M J, CARDILLO T M, et al.. CD74: a new candidate target for the immunotherapy of B-cell neoplasms[J]. Clin. Cancer Res., 2007, 13(18): 5556-5563. | 
																													
																							| 16 | OCHAKOVSKAYA R, OSORIO L, GOLDENBERG D M, et al.. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90).ttrium[J]. Clin. Cancer Res., 2001, 7(6): 1505-1510. | 
																													
																							| 17 | SAPRA P, STEIN R, PICKETT J, et al.. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys[J]. Clin. Cancer Res., 2005, 11(14): 5257-5264. | 
																													
																							| 18 | CHANG C H, SAPRA P, VANAMA S S, et al.. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin[J]. Blood, 2005, 106(13): 4308-4314. | 
																													
																							| 19 | BORGHESE F, CLANCHY F I. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease[J]. Expert Opin. Ther. Targets, 2011, 15(3): 237-251. |